Novavax’s alliance with Sanofi came at an opportune time for the beleaguered vaccine developer. Its protein-based Covid-19 vaccine never reached the revenue highs achieved by the messenger RNA ...
Shah Capital frustrated with Novavax's weak COVID-19 vaccine sales Hedge fund increases stake to 8.3%, urges sale to large pharma Novavax's COVID vaccine sales lag behind competitors Nov 13 (Reuters) ...
Vaccine biotechnology company Novavax (NASDAQ:NVAX) in Q3 CY2025, but sales fell by 16.6% year on year to $70.45 million. The company expects the full year’s revenue to be around $1.05 billion, close ...
GAITHERSBURG, Md., Sept. 30, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced progress on its collaboration and license agreement (CLA) with Sanofi regarding Novavax's (NVAX) Matrix-M ...
Novavax, Inc. receives a Hold rating, reflecting improved prospects after its Sanofi partnership and upgraded 2025 revenue guidance to $1–1.05 billion. The SNY deal provides upfront payments, ...
Peer-reviewed data shows Novavax's H5N1 vaccine candidate demonstrated immunogenicity against currently circulating variants following either single or two-dose administration Potential for single ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results